Evidence map›Paper›PMID 30651369›Full record

ArticleJournal of virology2019

The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.

Wuxun Lu, Shuliang Chen, Jingyou Yu, Ryan Behrens, Joshua Wiggins, Nathan Sherer, Shan-Lu Liu, Yong Xiong, Shi-Hua Xiang, Li Wu

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wuxun Lu *Center for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
Shuliang Chen *Center for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
Jingyou YuCenter for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
Ryan BehrensMcArdle Laboratory for Cancer Research and Institute for Molecular Virology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Joshua WigginsSchool of Veterinary Medicine and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
Nathan ShererMcArdle Laboratory for Cancer Research and Institute for Molecular Virology, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-9974-236X
Shan-Lu LiuCenter for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
Yong XiongDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
Shi-Hua XiangSchool of Veterinary Medicine and Biomedical Sciences, Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
Li WuCenter for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA wu.840@osu.edu.ORCID 0000-0002-5468-2487
The Ohio State University · USUniversity of Nebraska–Lincoln · USUniversity of Wisconsin–Madison · USYale University · US

Funding

Training Program In Molecular AND Cellular PharmacologyT32GM008688 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI AUDHYA, ANJON · 1998 to 2020
$6.0M
The Cell Biology of HIV-1 Genome TraffickingR01AI110221 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI Nathan M Sherer · 2014 to 2026
$4.4M
Virology Training ProgramT32AI078985 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI LAMBERT, PAUL F. · 2009 to 2018
$3.3M
IFITM-mediated Inhibition of HIV Infection and Viral CountermeasuresR01AI112381 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI LIU, SHAN-LU · 2014 to 2018
$1.7M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by NefR01AI150473 · NIAID · OHIO STATE UNIVERSITY · PI LIU, SHAN-LU · 2019 to 2021
$995k
Mechanisms of HIV-1 RNA Methylation in Regulating Viral ReplicationR01GM128212 · NIGMS · OHIO STATE UNIVERSITY · PI WU, LI · 2017 to 2018
$831k
Mechanisms of HIV-1 RNA Methylation in Regulating Viral ReplicationR01AI150343 · NIAID · UNIVERSITY OF IOWA · PI WU, LI · 2019 to 2020
$768k
HIV-1 Nef Interaction with Nef-associated Factor 1 Regulates Viral LatencyR01AI120209 · NIAID · OHIO STATE UNIVERSITY · PI WU, LI · 2015 to 2017
$600k
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by NefR01GM132069 · NIGMS · OHIO STATE UNIVERSITY · PI LIU, SHAN-LU · 2018 to 2018
$332k
NIAID NIH HHS R01 AI110221NIAID NIH HHS R01 AI112381NIAID NIH HHS R01 AI120209NIAID NIH HHS R01 AI150343NIAID NIH HHS R01 AI150473NIAID NIH HHS T32 AI078985NIGMS NIH HHS R01 GM128212NIGMS NIH HHS R01 GM132069NIGMS NIH HHS T32 GM008688NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

HIV-1 enters cells through binding between viral envelope glycoprotein (Env) and cellular receptors to initiate virus and cell fusion. HIV-1 Env precursor (gp160) is cleaved into two units noncovalently bound to form a trimer on virions, including a surface unit (gp120) and a transmembrane unit (gp41) responsible for virus binding and membrane fusion, respectively. The polar region (PR) at the N terminus of gp41 comprises 17 residues, including 7 polar amino acids. Previous studies suggested that the PR contributes to HIV-1 membrane fusion and infectivity; however, the precise role of the PR in Env-mediated viral entry and the underlying mechanisms remain unknown. Here, we show that the PR is critical for HIV-1 fusion and infectivity by stabilizing Env trimers. Through analyzing the PR sequences of 57,645 HIV-1 isolates, we performed targeted mutagenesis and functional studies of three highly conserved polar residues in the PR (S532P, T534A, and T536A) which have not been characterized previously. We found that single or combined mutations of these three residues abolished or significantly decreased HIV-1 infectivity without affecting viral production. These PR mutations abolished or significantly reduced HIV-1 fusion with target cells and also Env-mediated cell-cell fusion. Three PR mutations containing S532P substantially reduced gp120 and gp41 association, Env trimer stability, and increased gp120 shedding. Furthermore, S532A mutation significantly reduced HIV-1 infectivity and fusogenicity but not Env expression and cleavage. Our findings suggest that the PR of gp41, particularly the key residue S532, is structurally essential for maintaining HIV-1 Env trimer, viral fusogenicity, and infectivity.

Indexed as

Cell LineCell Line, Tumorenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHeLa CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HIV InfectionsHumansVirionVirus Internalizationenv Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp120HIV Envelope Protein gp41entryenvelope glycoproteinfusiongp160gp41HIV-1infectivitypolar regiontrimer

Identifiers

PMID30651369
PMCPMC6430531
OpenAlexW2910927042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.